Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma

Zhao,Fuyou; Wu,Qiong; Dai,Xiusong; Li,Yumei; Gan,Huaiyong; Wang,Ri; Lv,Jie; Chen,Yuqing

doi:10.3892/ol.2016.5311

Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma

Authors:
- Fuyou Zhao
- Qiong Wu
- Xiusong Dai
- Yumei Li
- Huaiyong Gan
- Ri Wang
- Jie Lv
- Yuqing Chen
View Affiliations

Affiliations: Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, P.R. China, Department of Orthopedics, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, P.R. China, Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, P.R. China, Department of Microbiology, Bengbu Medical College, Bengbu, Anhui 233000, P.R. China, Department of Respiratory Diseases, The Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, P.R. China
Published online on: October 24, 2016 https://doi.org/10.3892/ol.2016.5311
Pages: 5199-5204

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of programmed cell death 1 (PD‑1) on osteosarcoma (OD) stem cells and T cells, and to determine their correlation. OS stem cells were sorted and identified from OS MG63 cells. Flow cytometry was used to detect the PD‑1 expression of the OS tumor stem cell membrane surface. The expression of PD‑1 mRNA was detected by reverse transcription‑polymerase chain reaction (RT‑PCR). MTT was used to detect the effect of PD‑1 signals on T‑cell proliferation. The results indicated that the cancer cells (cultured in DMEM medium containing 10% fetal bovine serum) exhibited clear proliferation within 1 week of cell culture, which showed their strong proliferation and aggressive ability. The formation of tumor cell spheres was dependent on the support of serum nutrition. The proliferation of MG63 cells in the serum culture medium was significantly higher than the number of OS cell spheres in serum‑free suspension culture (P<0.05). Pluripotent stem cells in cancer cell spheres exhibited significantly higher cluster of differentiation 133 expression compared with the MG63 cells. The PD‑1 expression levels of the cancer cell spheres was significantly increased compared with the MG63 cells, which is consistent with the results of the RT‑PCR. In conclusion, the MG63 cell line possesses the features of OS stem cells. The MG63 cell line can express the certain cancer‑associated cell markers. The expression of PD‑1 in spheres was also increased significantly compared to the MG63 cells, which can reduce the immune function of patients and may be closely associated with the occurrence and development of tumors.

View Figures

View References

1	Bai X, Meng H, Ma L and Guo A: Inhibitory effects of evodiamine human osteosarcoma cell proliferation and apoptosis. Oncol Lett. 9:801–805. 2015.PubMed/NCBI
2	Fleuren ED, Versleijen-Jonkers YM, Boerman OC and van der Graaf WT: Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives. Biochim Biophys Acta. 1845:266–276. 2014.PubMed/NCBI
3	Botter SM, Neri D and Fuchs B: Recent advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014. View Article : Google Scholar : PubMed/NCBI
4	Siewe B, Wallace J, Rygielski S, Stapleton JT, Martin J, Deeks SG and Landay A: Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs. PLoS One. 9:e929342014. View Article : Google Scholar : PubMed/NCBI
5	Xu P, Chen YJ, Chen H, Zhu XY, Song HF, Cao LJ and Wang XF: The expression of programmed death-1 in circulating CD4⁺ and CD8⁺ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver. 8:186–195. 2014. View Article : Google Scholar : PubMed/NCBI
6	Philip NH, Dillon CP, Snyder AG, Fitzgerald P, Wynosky-Dolfi MA, Zwack EE, Hu B, Fitzgerald L, Mauldin EA, Copenhaver AM, et al: Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-kB and MAPK signaling. Proc Natl Acad Sci USA. 11:7385–7590. 2014. View Article : Google Scholar
7	Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ and Mor A: Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 153:145–152. 2014. View Article : Google Scholar : PubMed/NCBI
8	Notaro A, Sabella S, Pellerito O, Di Fiore R, De Blasio A, Calvaruso G and Giuliano M: Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis. Int J Biol Sci. 10:466–478. 2014. View Article : Google Scholar : PubMed/NCBI
9	Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y and Furue M: Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival. J Am Acad Dermatol. 70:954–956. 2014. View Article : Google Scholar : PubMed/NCBI
10	Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al: PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2:361–370. 2014. View Article : Google Scholar : PubMed/NCBI
11	Joseph RW, Parasramka M, Eckel-Passow JE, Seri D, Wu K, Jiang L, Kalari K, Thompson RJ, Huu Ho T, Castle EP, et al: Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. Cancer Immunol Res. 1:378–385. 2013. View Article : Google Scholar : PubMed/NCBI
12	Macfarlane AW IV, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T and Campbell KS: PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res. 2:320–331. 2014. View Article : Google Scholar : PubMed/NCBI
13	Flies DB, Han X, Higuchi T, Zheng L, Sun J, Ye JJ and Chen L: Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity. J Clin Invest. 124:1966–1975. 2014. View Article : Google Scholar : PubMed/NCBI
14	Barker CA and Postow MA: Combinations of radiation therapy and immunotherapy for melanoma: A review of clinical outcomes. Int J Radiat Oncol Biol Phys. 88:986–997. 2014. View Article : Google Scholar : PubMed/NCBI
15	Tosti G, Cocorocchio E and Pennacchioli E: Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol. 6:245–256. 2013.PubMed/NCBI
16	Feng D, Yang X, Li S, Liu T, Wu Z, Song Y, Wang J, Gao W, Huang Q, Huang W, et al: Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma. Genet Test Mol Biomarkers. 17:458–463. 2013. View Article : Google Scholar : PubMed/NCBI
17	Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, Song W and Yuan W: Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 30:1051–1055. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wang W, Wang J, Song H, Liu J, Song B and Cao X: Cytotoxic T-lymphocyte antigen-4⁺ 49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 15:503–506. 2011. View Article : Google Scholar : PubMed/NCBI
19	Yang S, Wang C, Zhou Y, Sun G, Zhu D and Gao S: Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to Ewing's sarcoma. Genet Test Mol Biomarkers. 16:1236–1240. 2012. View Article : Google Scholar : PubMed/NCBI
20	Shang Y, Li Z, Li H, Xia H and Lin Z: TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers. Oncol Lett. 6:490–494. 2013.PubMed/NCBI
21	Ramsay AG: Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 162:313–325. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ott PA, Hodi FS and Robert C: CTLA-4 and PD-1/PDL1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 19:5300–5309. 2013. View Article : Google Scholar : PubMed/NCBI
23	Okazaki T, Chikuma S, Iwai Y, Fagarasan S and Honjo T: A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 14:1212–1218. 2013. View Article : Google Scholar : PubMed/NCBI
24	Pan XC, Li L, Mao JJ, Yao W, Zheng JN, Liu M and Fu JJ: Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma. Oncol Lett. 5:90–96. 2013.PubMed/NCBI